找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Lung Cancer:; Prevention, Manageme David J. Stewart Book 2010 Humana Press 2010 Antiangiogenesis.Cancer.Carcinom.Clinical trials.Lung.Malig

[復(fù)制鏈接]
查看: 52476|回復(fù): 58
樓主
發(fā)表于 2025-3-21 19:41:46 | 只看該作者 |倒序瀏覽 |閱讀模式
書目名稱Lung Cancer:
副標(biāo)題Prevention, Manageme
編輯David J. Stewart
視頻videohttp://file.papertrans.cn/590/589062/589062.mp4
概述Provides full coverage of established and emerging therapies, including novel targeted and antiangiogenic agents.Evaluates the mechanisms of drug resistance and the therapeutic potential of new target
叢書名稱Current Clinical Oncology
圖書封面Titlebook: Lung Cancer:; Prevention, Manageme David J. Stewart Book 2010 Humana Press 2010 Antiangiogenesis.Cancer.Carcinom.Clinical trials.Lung.Malig
描述Defining the Lung Cancer Problem 1 Lung cancer is the leading cause of cancer death in the world. It kills almost as many Americans as cancers of the breast, prostate, colon, rectum, pancreas, and 2 kidney combined, and accounts for 28.6% of all US cancer deaths. With an increase in the 5-year relative survival rate from 13% to only 16% in the more than 2 30 years from 1974 to the present, it will take us another 840 years to eradicate lung cancer deaths if we do not improve the current rate of progress. As discussed in this text, lung cancer prevention has received substantial att- tion. The decrease in smoking in recent decades has helped, but smoking is not the only problem. Lung cancer in people who have never smoked is currently the 5th 3 leading cause of cancer death in the United States. Several factors contribute to the lethality of lung cancer, including the rapidity of tumor growth, advanced stage at diagnosis (due to nonspecificity of early sy- toms and the uncertain efficacy of screening), early development of metastases, and resistance to therapy. Several chapters in this book discuss new molecular targets that may be potentially exploitable in the future, as well as d
出版日期Book 2010
關(guān)鍵詞Antiangiogenesis; Cancer; Carcinom; Clinical trials; Lung; Malignancy; Mesothelioma; Non-small cell lung ca
版次1
doihttps://doi.org/10.1007/978-1-60761-524-8
isbn_softcover978-1-61779-684-5
isbn_ebook978-1-60761-524-8Series ISSN 2364-1134 Series E-ISSN 2364-1142
issn_series 2364-1134
copyrightHumana Press 2010
The information of publication is updating

書目名稱Lung Cancer:影響因子(影響力)




書目名稱Lung Cancer:影響因子(影響力)學(xué)科排名




書目名稱Lung Cancer:網(wǎng)絡(luò)公開度




書目名稱Lung Cancer:網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Lung Cancer:被引頻次




書目名稱Lung Cancer:被引頻次學(xué)科排名




書目名稱Lung Cancer:年度引用




書目名稱Lung Cancer:年度引用學(xué)科排名




書目名稱Lung Cancer:讀者反饋




書目名稱Lung Cancer:讀者反饋學(xué)科排名




單選投票, 共有 0 人參與投票
 

0票 0%

Perfect with Aesthetics

 

0票 0%

Better Implies Difficulty

 

0票 0%

Good and Satisfactory

 

0票 0%

Adverse Performance

 

0票 0%

Disdainful Garbage

您所在的用戶組沒有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 20:53:26 | 只看該作者
Other Molecular Targeted Agents in Non-small Cell Lung Cancer,ir role in angiogenesis, (5) Bcl-2 and death receptors in the apoptotic field. We discuss the challenges that we are facing to implement these new drugs among the approved drugs and validated strategies.
板凳
發(fā)表于 2025-3-22 02:20:48 | 只看該作者
地板
發(fā)表于 2025-3-22 07:39:55 | 只看該作者
2364-1134 drug resistance and the therapeutic potential of new targetDefining the Lung Cancer Problem 1 Lung cancer is the leading cause of cancer death in the world. It kills almost as many Americans as cancers of the breast, prostate, colon, rectum, pancreas, and 2 kidney combined, and accounts for 28.6% o
5#
發(fā)表于 2025-3-22 10:32:56 | 只看該作者
6#
發(fā)表于 2025-3-22 13:17:38 | 只看該作者
Gene-Based Therapies for Lung Cancer,linical developments involving gene-based targeted therapies in lung cancer. Discussion will focus on replacement therapies for abnormal p53 function, FUS1 mediated molecular therapy, antisense technologies, and early developments with RNA interference technology.
7#
發(fā)表于 2025-3-22 19:13:16 | 只看該作者
Palliative Care for Patients with Lung Cancer,n, fatigue, cough, hemoptysis, anorexia, cachexia, depression, and anxiety, can usually be managed effectively. For patients with severe symptoms or psychosocial distress, early involvement of the palliative care team is essential.
8#
發(fā)表于 2025-3-23 00:19:48 | 只看該作者
Lung Cancer Prevention, done in the last few decades, analyzes the reasons for their failure, and reviews the future directions and the targeted therapy that may be potentially relevant in the chemoprevention of lung cancer.
9#
發(fā)表于 2025-3-23 02:44:57 | 只看該作者
Angiogenesis Inhibitors in Lung Cancer,terest in developing novel molecular-targeted agents that inhibit the angiogenic pathway. The aim of this chapter is to summarize the data for agents that have been approved and are in development for the treatment of patients with NSCLC and small cell lung cancer (SCLC).
10#
發(fā)表于 2025-3-23 06:22:19 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-6 01:30
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
济宁市| 苗栗市| 玛纳斯县| 台州市| 尼勒克县| 江孜县| 永仁县| 友谊县| 怀仁县| 崇仁县| 蓝田县| 通许县| 太仆寺旗| SHOW| 尉氏县| 永济市| 天峨县| 肥乡县| 宿松县| 泸水县| 定兴县| 广灵县| 平邑县| 图木舒克市| 新巴尔虎右旗| 永丰县| 绵阳市| 白河县| 尉犁县| 阳曲县| 舟曲县| 桃园市| 佛山市| 禹州市| 广昌县| 博野县| 南江县| 积石山| 博湖县| 微山县| 桑日县|